Bonham's lab is interested in the regulation of gene expression, especially at the level of transcription, in cancer cells. Associate Professor, Department of Surgery, University of Saskatchewan Director, Laboratory of Oral, Head & Neck Cancer – Personalized Diagnostics and Therapeutics Office: Room 4D10.2Phone: (306) [email protected]
His lab works on a number of model genes including SRC, MYC and FRK. Silvana Papagerakis is an established clinician-scientist in the field of oral, head and neck cancer with over 20 years of research success in basic, translational and clinical research within research intensive academic health settings.
We are primarily involved in processing the genomic data, describing the genetic properties of the resource, and developing the analytical tools for QTL mapping using the DSPR.
For much more information, visit Allocation strategies are highly complex traits and require a systems level approach to uncovering their genetic basis.
Synthetic Population Resource (DSPR) is a large collection of recombinant inbred lines derived from an 8-way 50 generation intercross.
This design creates a panel of lines whose genomes are a mosaic of the original 8 founder lines, allowing for unprecedented mapping resolution for a linkage-based panel.
This underlying complexity makes identifying most of the causative genetic variants very challenging.The transparency of the animal makes it feasible to use genetically encoded calcium sensors to monitor neural activity in response to sensory stimuli.Transgenic expression of allows us to turn neurons on and off.He is particularly interested in epigenetics and the ability of certain drugs, such as Histone Deacetylase Inhibitors, to reprogram gene expression in cancer cells leading to cell death. Bonham has shown such drugs are capable of repressing the transcription of potent oncogenes such as SRC, MYC and others while simultaneously inducing regulators of cell cycle arrest and apoptosis. Bonham has been exploring other epigenetic mechanism such as differential methylation in the regulation of a potential tumour suppressor gene, FRK. Lukong’s lab is centred on breast tumour kinase (BRK) and two other BRK family members, FRK and SRMS. Her expertise encompasses qualitative and quantitative patient oriented research; cancer epidemiology, prevention and control; clinical trials; outcomes prediction; anti-cancer drug reformulation and personalized therapeutics; precision molecular medicine; chemical and viral (e.g.BRK is overexpressed in the majority of breast carcinomas and tends to function as an oncogene, while FRK displays tumor suppressor activity in breast cancer. The Lukong lab is investigating the cellular and physiological roles, and the mechanisms of action and modes of regulation of all three kinases in breast cancer. Human Papillomavirus) carcinogenesis; epigenetics; tumor heterogeneity, microenvironment and metabolism; in vivo an in vitro experimental models.